Integrated Filing — IndAS



General information about company

Scrip Code 524075
NSE Symbol ALBERTDAVD
MSEI Symbol NOTLISTED
ISIN INE155C01010
Name of company ALBERT DAVID LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 01-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 12-11-2025   11:00:00
End date and time of board meeting 12-11-2025   15:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 14-03-2024
Indicate Company website link for updated RPT policy of the Company https://www.albertdavidindia.com/policies.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NIL



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 8,724.13 15,780.77
Other income (214.38) 1,989.24
Total income 8,509.75 17,770.01
2 Expenses
(a) Cost of materials consumed 1,198.68 2,523.48
(b) Purchases of stock-in-trade 1,045.31 2,036.53
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 821.30 1,033.28
(d) Employee benefit expense 2,707.46 5,550.48
(e) Finance costs 75.07 130.55
(f) Depreciation, depletion and amortisation expense 222.82 461.69
(f) Other Expenses
1 Other Expenses 2,697.32 5,448.38
Total other expenses 2,697.32 5,448.38
Total expenses 8,767.96 17,184.39
3 Total profit before exceptional items and tax (258.21) 585.62
4 Exceptional items 0.00 0.00
5 Total profit before tax (258.21) 585.62
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 71.96 122.03
9 Total tax expenses 71.96 122.03
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (330.17) 463.59
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (330.17) 463.59
17 Other comprehensive income net of taxes (18.53) (36.89)
18 Total Comprehensive Income for the period (348.70) 426.70
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 570.72 570.72
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -5.79 8.12
Diluted earnings (loss) per share from continuing operations -5.79 8.12
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -5.79 8.12
Diluted earnings (loss) per share from continuing and discontinued operations -5.79 8.12
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 12th November, 2025. The Limited Review for the quarter and half year ended 30th September, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015. 2. The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter and Half Year ended 30th September,2025. 3. The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 Operating Segments. 4. During the quarter the Company has made payment of dividend of Rs.5.00 per equity share of Rs.10/- each, total outflow amounting to Rs.285.36 Lakhs in respect of financial year ended on 31st March, 2025. 5. Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 9,447.34
Capital work-in-progress 521.25
Investment property 0.00
Goodwill 0.00
Other intangible assets 71.48
Intangible assets under development 20.43
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 1,759.09
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 1,590.08
Total non-current financial assets 3,349.17
Deferred tax assets (net) 0.00
Other non-current assets 170.01
Total non-current assets 13,579.68
2 Current assets
Inventories 5,145.80
Current financial asset
Current investments 25,908.42
Trade receivables, current 4,158.01
Cash and cash equivalents 89.33
Bank balance other than cash and cash equivalents 2,431.01
Loans, current 402.15
Other current financial assets 405.48
Total current financial assets 33,394.40
Current tax assets (net) 560.92
Other current assets 613.26
Total current assets 39,714.38
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 53,294.06
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 570.72
Other equity 38,818.94
Total equity attributable to owners of parent 39,389.66
Non controlling interest
Total equity 39,389.66
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 87.66
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 122.90
Total non-current financial liabilities 210.56
Provisions, non-current 566.43
Deferred tax liabilities (net) 735.43
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 1,512.42
Current liabilities
Current financial liabilities
Borrowings, current 4,053.72
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 180.49
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,669.67
Total Trade payable 2,850.16
Other current financial liabilities 3,055.14
Total current financial liabilities 9,959.02
Other current liabilities 316.52
Provisions, current 2,116.44
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 12,391.98
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 13,904.40
Total equity and liabilites 53,294.06
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -2476000 -4930000
Total Amount of items that will not be reclassified to profit and loss (24.76) (49.30)
2 Income tax relating to items that will not be reclassified to profit or loss (6.23) (12.41)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (18.53) (36.89)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 585.62
Adjustments for reconcile profit (loss)
Adjustments for finance costs 130.55
Adjustments for decrease (increase) in inventories 1,244.40
Adjustments for decrease (increase) in trade receivables, current (1,424.37)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 236.60
Adjustments for other financial assets, non-current (12.56)
Adjustments for other financial assets, current 29.49
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (892.65)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (78.34)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 461.69
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (7.93)
Adjustments for dividend income (9.27)
Adjustments for interest income (184.88)
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (1,768.41)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (388.30)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (2,275.68)
Net cash flows from (used in) operations (1,690.06)
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 394.49
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (2,084.55)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 12.99
Purchase of property, plant and equipment (627.58)
Proceeds from sales of investment property 81.16
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 9.27
Interest received 231.50
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,317.25)
Net cash flows from (used in) investing activities (354.75)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings (2,946.86)
Payments of lease liabilities 57.40
Dividends paid 283.08
Interest paid 118.16
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 2,488.22
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 48.92
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 48.92
Cash and cash equivalents cash flow statement at beginning of period 40.41
Cash and cash equivalents cash flow statement at end of period 89.33





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 L B Jha & Co. Yes 31-01-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Albert David Limited Gillander Arbuthnot and Company Limited Company in which KMP/Director has significant influence Purchase of goods or services 60.00 Not Applicable 24.00 0.00 0.00
2 Albert David Limited Strategic Marketing Solutions & Research Centre Private Limited Company in which KMP/Director has significant influence Purchase of goods or services 35.00 Not Applicable 12.50 0.00 0.00
3 Albert David Limited Medclin Research Pvt. Ltd. Company in which KMP/Director has significant influence Purchase of goods or services 23.00 Not Applicable 6.48 0.00 0.00
4 Albert David Limited Kothari Medical Centre Trust in which KMP has significant influence Any other transaction Donation Paid 200.00 Not Applicable 50.00 0.00 0.00
5 Albert David Limited Mr. Arun Kumar Kothari Chairman & Executive Director Remuneration 129.86 Not Applicable 129.86 0.00 0.00
6 Albert David Limited Mrs. Prabhawati Devi Kothari Non-Executive Director Any other transaction Sitting fees 10.00 Not Applicable 0.70 0.00 0.00
7 Albert David Limited Mr. Anand Vardhan Kothari Non-Executive Director Any other transaction Sitting fees 10.00 Not Applicable 0.50 0.00 0.00
8 Albert David Limited Kothari Phytochemicals & Industries Ltd. Company in which KMP/Director has significant influence Any other transaction Sale of Equity Shares 500.00 Not Applicable 99.99 0.00 0.00
9 Albert David Limited PDK Family Trust Company in which KMP/Director has significant influence Any other transaction Sale of Equity Shares 500.00 Not Applicable 14.98 0.00 0.00
Total value of transaction during the reporting period 339.01